Affluent Medical to Merge with Caranx Medical and Artedrone in €280M Deal, Forming New Cardiovascular and Neurovascular Platform Carvolix

Recently,Affluent MedicalAnnounced that it has respectively signed agreements with Caranx MedicalAnd ArtedroneReach an acquisition agreement. After the transaction is completed, Affluent plans to integrate the three companies into a brand-new cardiovascular and neurointerventional technology platform company——Carvolix。

According to the disclosed information, Affluent Medical will be at approximately 16.60 million euros(Approximately RMB 138 million)Acquisition of Caranx Medical for approximately11.40 million euros(Approximately RMB94.36 million)Acquisition of Artedrone, both transactions were conducted usingIn the form of a share issuance as payment (cashless transaction), and includes a contingent value right (CVR) linked to future developments. The transaction is expected to be completed inEarly 2026Completed, and subject to approval by the shareholders' meeting.

From the perspective of structure and rhythm, this appears to be a highly "designed" platform-level restructuring under the Truffle Capital system.

# Transaction Structure: Competing on Corporate Capabilities

First, it needs to be clarified that in this transaction:

• Caranx Medical is a company focused onRobot-Assisted Transcatheter Aortic Valve Implantation (TAVI)The Company

• Artedrone is also a company focused onAutonomous Miniature Robot for Mechanical Thrombectomy in StrokeThe Company

• Affluent Medical itself hasWith multiple cardiovascular and functional implant products at various stages

In other words, Affluent Medical did not acquire a single technology or product, but instead integrated everything at once.Three technology companies that have completed early validation in different interventional scenarios, and after the completion of the transaction, a new unified platform – Carvolix – will be formed through the reorganization at the brand and organizational levels.

In terms of payment method, Affluent chose to complete the transaction through a stock swap rather than cash, which not only reduced short-term financial pressure but also created a deeper alignment of interests for the original team within the new company. This structure aligns with Truffle Capital's consistent approach.“business builder”Model: Reduce the risk of single-point innovation failure through capital and organizational integration.

# The "Puzzle Capabilities" Brought by Three Companies Respectively

From the perspective of capability structure, the three companies are not simply stacked together but occupy different key positions in the interventional treatment chain.

Affluent MedicalPositioned as "an implantable device company addressing significant unmet clinical needs," its current product pipeline covers multiple areas including heart valves, blood vessels, and functional implants. Among these, the mitral valve annuloplasty device Kalios has reached a cooperation agreement with Edwards Lifesciences and received upfront payment support, providing practical endorsement for its commercialization pathway.

Caranx MedicalThe core value lies in its software and robotic capabilities built around the TAVI surgical procedure. Its development ofTavipilot Software, has received FDA approval and completed its first commercial application. The goal of this software is not to "replace doctors' decision-making," but to improve the predictability and consistency of the valve implantation process through imaging, path planning, and algorithmic assistance. In addition, Caranx is still advancing its accompanying TAVI interventional robotic system.

ArtedroneFocuses on another high-difficulty but highly operation-dependent scenario — mechanical thrombectomy for stroke. The research and development direction isAutonomous Miniature RobotsThe goal is not to raise the "technical ceiling" of individual surgeries, but to reduce the reliance on centralized experience and the number of doctors, thereby increasing the accessibility of this treatment across more medical institutions.

From this perspective, the three companies correspond to three different but highly related issues:How to Standardize, Scale, and Safely Implement Complex Interventional Surgeries in More Centers。

# Carvolix's Product Logic: Software First, Then Robotics, Then Systematization

Notably, Affluent Medical did not rush to depict a "completely disruptive" product roadmap in its disclosure but instead provided a relatively clear sequence of progress.

Within the foreseeable stage, the focus of Carvolix will be on:

1. Commercialization Progress of Approved Products
   

For example Tavipilot Software, planning to launch a wider range of commercial applications in the U.S. market in the first quarter of 2026.

2. Clinical and Engineering Iteration of Robotic Systems

Including interventional robots for TAVI and the Artedrone system for stroke thrombectomy.

3. Synergize with existing implant products

Integrating robotics with software capabilities, withAffluent Existing Valves, Catheters, and Implant PipelinesIntegrate, rather than operate independently.

This path is not radical, but the advantage lies in:Every step is supported by existing clinical scenarios and unmet needs.。

# Why "Merge into a New Company"

A key word repeatedly mentioned in Affluent's announcement is:Upgrade Cardiac Catheterization Laboratory。

The reality behind this is that in multiple high-value interventional fields，There is still a significant gap between treatment penetration and the scale of potential patients.：

• The proportion of patients suitable for TAVI who actually undergo the procedure remains at a relatively low level.

• In patients with ischemic stroke, the accessibility of mechanical thrombectomy highly depends on center capability.

• In patients with severe mitral regurgitation, the proportion receiving interventional treatment is also limited.

These gaps are not entirely due to whether the technology itself exists, but rather more fromSurgical Complexity, Operational Threshold, and System Capability LimitationsCarvolix is not trying to "recreate a more difficult high-end technology," but rather to lower the barriers to using these technologies in the real world through automation, navigation, and robotics.

# Conclusion: A Structural Integration, Not a Single-Point Technology Bet

Overall, Affluent Medical's acquisition of Caranx Medical and Artedrone is not a high-stakes gamble centered around a "star product," but rather aStructural Selection：

• By integrating multiple companies to diversify R&D and commercialization risks

• By unifying the platform, improve technical collaboration and capital readability

• By proceeding step-by-step, avoid prematurely amplifying technical promises.

Whether Carvolix can ultimately fulfill its vision remains to be seen through long-term clinical and market validation. However, at least from the perspective of this transaction itself, the integration within the Truffle Capital system,Not in a rush to make noise, but more like building a more complete solution framework for a long-standing interventional treatment structural issue.。